Lynn Huynh
 
                    Education
Dr.P.H., epidemiology, and M.P.H., concentration in epidemiology and biostatistics, Johns Hopkins Bloomberg School of Public Health; M.B.A., concentration in health economics, Johns Hopkins Carey Business School; B.A., chemistry, Harvard University
Summary of Experience
Dr. Huynh specializes in epidemiologic methodologies and health economics and outcomes research (HEOR), and has extensive experience collecting real-world clinical data through medical charts using center-based and physician panel-based approaches. She has conducted comparative effectiveness and cost-effectiveness research on various diseases, including aplastic anemia, asthma, chronic lymphocytic leukemia, chronic myelogenous leukemia, colorectal cancer, dry eye disease, dysfunctional uterine bleeding, epilepsy, hemophilia, hepatitis B, HIV, inflammatory bowel disease, lung cancer, metachromatic leukodystrophy, myelofibrosis, multiple sclerosis, neuroendocrine tumors, non-Hodgkin’s lymphoma, primary open-angle glaucoma, renal cell carcinoma, sickle cell disease, and thromboembolism. Dr. Huynh has experience designing and developing case report forms, coordinating with clinical centers for data collection, developing discrete choice experiment surveys, designing quality of life and humanistic burden surveys, leading qualitative interviews, performing mixed methods research, performing systematic reviews, analyzing longitudinal cohort studies, and developing discrete event simulation models and economic evaluations. She has been involved in conducting several real-world evidence studies to examine the natural history of disease progression in order to contextualize the results of single-arm trials in support of regulatory new drug application (NDA) or supplemental NDA submissions.
- 
                                                        IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidenceBlood Advances, 2024 
 2024Soumerai JD, Yousif Z, Gift T, Desai R, Huynh L, Ye M, Banatwala A, Clear L, Pinaire M, Belsky G, Grace Hsieh YG, Herrick C, Darnell EP, Duh MS, Sanchirico M, Murphy SN 
- 
                                                        Real-world effectiveness of dupilumab versus benralizumab and mepolizumabAllergy & Asthma Proceedings, 2024 
 2024Bleecker E, Blaiss M, Jacob-Nara J, Huynh L, Guo T, Ye M, Stanford RH, Wang Z, Soler X, Nag A, Nair R, Borsos K 
- 
                                                        Burden of eosinophilic granulomatosis with polyangiitis in EuropeERJ Open Research, 2024 
 2024Jakes RW, Kwon N, Huynh L, Hwee J, Baylis L, Alfonso-Cristancho R, Du S, Khanal A, Duh MS, Terrier B 
- 
                                                        Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: Real-world US ADVANTAGE studyThe Journal of Allergy and Clinical Immunology, 2024 
 2024Bleecker E, Blaiss M, Jacob-Nara J, Huynh L, Duh MS, Guo T, Ye M, Stanford RH, Wang Z, Soler X, Nag A, Nair R, Borsos K 
- 
                                                        Hypereosinophilic Syndrome in Europe: Retrospective Study of Treatment Patterns, Clinical Manifestations, and Healthcare Resource UtilizationAnnals of Allergy, Asthma & Immunology, 2023 
 2023Hwee J, Huynh L, Du S, Kwon N, Jakes RW, Alfonso-Cristancho R, Baylis L, Requena G, Khanal A, Rothenberg MC, Duh MS 
- 
                                                        
- 
                                                        Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect ComparisonAdvances in Therapy, 2023 
 2023Wong R, Fishman J, Wilson K, Yeh M, Al-Adhami M, Zion A, Yee CW, Huynh L, Duh MS 
- 
                                                        Impact of Therapy Management on Axitinib-Related Adverse Events in Patients with Advanced Renal Cell Carcinoma Receiving First-Line Axitinib + checkpoint InhibitorClinical Genitourinary Cancer, 2023 
 2023Zakharia Y, Huynh L, Du S, Chang R, Pi S, Sundaresan S, Duh MS, Zanotti G, Thomaidou D 
- 
                                                        A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I MutationCancers, 2023 
 2023Nicolini FE, Huguet F, Huynh L, Xu C, Bouvier C, Yocolly A, Etienne G 
- 
                                                        Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysisBMC Ophthalmology, 2023 
 2023Karpecki P, Barghout V, Schenkel B, Huynh L, Khanal A, Mitchell B, Yenikomshian M, Zanardo E, Matossian C 
- 
                                                        Literature Review of Fatigue Scales and Association with Clinically Meaningful Improvements in Outcomes Among Patients With and Without Paroxysmal Nocturnal HemoglobinuriaAdvances in Therapy, 2022 
 2022Krishnan S, Sarda S, Kunzweiler C, Wu M, Sundaresan S, Huynh L, Duh MS, Escalante CP 
- 
                                                        Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in EuropeCrohn's & Colitis 360, 2022 
 2022Huynh L, Hass S, Peyrin-Biroulet L, Duh MS, Sipsma H, Cheng M, Lax A, Nag A 
- 
                                                        Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world StudyClinical Genitourinary Cancer, 2021 
 2021Wells JC, Dudani S, Gan CL, Stukalin I, Azad AA, Liow E, Donskov F, Yuasa T, Pal SK, De Velasco G, Hansen AR, Beuselinck B, Kollmannsberger CK, Powles T, McGregor BA, Duh MS, Huynh L, Heng DYC 
- 
                                                        Real-world Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020Clinical Cancer Research, 2021 
 2021Arondekar B, Duh MS, Bhak R, DerSarkissian M, Huynh L, Wang K, Wojciehowski J, Wu M, Wornson B, Niyazov A, Demetri G 
- 
                                                        Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology CenterThe Oncologist, 2021 
 2021Patel AK, Abhyankar R, Brais LK, Duh MS, Barghout VE, Huynh L, Yenikomshian MA, Ng K, Fuchs CS 
- 
                                                        Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk GroupThe Oncologist, 2020 
 2020Savard MF, Wells JC, Graham J, Dudani S, Steinharter JA, McGregor BA, Donskov F, Bjarnason GA, Vaishampayan UN, Hansen AR, Iafolla MAJ, Zanotti G, Huynh L, Chang R, Duh MS, Heng DYC 
- 
                                                        Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review studyAnnals of Hematology, 2020 
 2020Peffault de Latour R, Huynh L, Ivanova JI, Totev T, Bilginsoy M, Antin J, Roy A, Duh MS 
- 
                                                        Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review StudyCancer Management and Research, 2020 
 2020Morse MA, Liu E, Joish VN, Huynh L, Cheng M, Duh MS, Seth K, Lapuerta P, Metz DC 
- 
                                                        Treatment patterns and deep molecular response in chronic phase - chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review studyLeukemia & Lymphoma, 2020 
 2020Cortes J, Huynh L, Mendelson E, Brandt P, Dalal D, DerSarkissian M, Cortina D, Narkhede S, Duh MS 
- 
                                                        Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcomaCancer, 2020 
 2020Gounder MM, Merriam P, Ratan R, Patel SR, Chugh R, Villalobos VM, Thornton M, Van Tine BA, Abdelhamid AH, Whalen J, Yang J, Rajarethinam A, Duh MS, Bobbili PJ, Huynh L, Totev TI, Lax AK, Agarwal S, Demetri GD 
- 
                                                        Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid SyndromeCancer Management and Research, 2020 
 2020Metz DC, Liu E, Joish VN, Huynh L, Totev TI, Duh MS, Seth K, Giacalone S, Lapuerta P, Morse MA 
- 
                                                        Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review StudyThe Oncologist, January 3, 2019 
 2019Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK 
- 
                                                        Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review StudyThe Oncologist, January 2019 
 2019Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH 
- 
                                                        Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell CarcinomaClinical Genitourinary Cancer, 2019 
 2019Wells JC, Graham J, Beuselinck B, Bjarnason GA, Donskov F, Hansen AR, McKay RR, Vaishampayan U, De Velasco G, Duh MS, Huynh L, Nguyen C, Zanotti G, Ramaswamy K, Choueiri TK, Heng DYC 
- 
                                                        
- 
                                                        Insights into the natural history of metachromatic leukodystrophy from interviews with caregiversOrphanet Journal of Rare Diseases, 2019 
 2019Harrington M, Whalley D, Twiss J, Rushton R, Martin S, Huynh L, Yang H 
- 
                                                        Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndromeBMC Cancer, 2019 
 2019Halperin DM, Huynh L, Beaumont JL, Cai B, Bhak RH, Narkhede S, Totev T, Duh MS, Neary MP, Cella D 
- 
                                                        Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint InhibitorsEuropean Urology Oncology, 2019 
 2019Graham J, Shah AY, Wells JC, McKay RR, Vaishampayan U, Hansen A, Donskov F, Bjarnason GA, Beuselinck B, De Velasco G, Iafolla M, Duh MS, Huynh L, Chang R, Zanotti G, Ramaswamy K, Choueiri TK, Tannir NM, Heng DYC 
- 
                                                        Value of transfusion independence in severe aplastic anemia from patients’ perspectives – a discrete choice experimentJournal of Patient-Reported Outcomes, 2018 
 2018Pickard AS, Huynh L, Ivanova JI, Totev T, Graham S, Mühlbacher AC, Roy A, Duh MS 
- 
                                                        Efficacy of antiepileptic drugs in the adjunctive treatment of refractory partial-onset seizures: Meta-analysis of pivotal trialsEpilepsy Research. 2018 Jul;143:120-129 
 2018Slater J, Chung S, Huynh L, Duh MS, Gorin B, McMicken C, Ziemann A, Isojarvi J 
- 
                                                        Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey studyMedicine, 2018 
 2018Halperin DM, Huynh L, Beaumont JL, Cai B, Totev T, Bhak RH, Duh MS, Neary MP, Cella D 
- 
                                                        Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practicesMedical Oncology. May 2017;34(5):88 
 2017Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary M, Bergsland E 
- 
                                                        Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LARJournal of Medical Economics. Jun 19 2017:1-7 
 2017
- 
                                                        Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with a(1)Journal of Medical Economics, 2017 
 2017
- 
                                                        February 23, 2024
- 
                                                    December 1, 2023
- 
                                                    March 2, 2023
- 
                                                    December 7, 2022
- 
                                                    July 19, 2022
